» Articles » PMID: 23503837

Oral Choline Tolerance Test As a Novel Noninvasive Method for Predicting Nonalcoholic Steatohepatitis

Abstract

Background: Although therapeutic intervention for nonalcoholic steatohepatitis (NASH) at an early stage is important owing to the progressive nature of the disease, diagnosis using noninvasive methods remains difficult. We previously demonstrated NASH specific impairment of choline metabolism and the use of fasting plasma free choline (fCh) levels for NASH diagnosis. Here, we investigated the utility of an oral choline tolerance test (OCTT), based on disordered choline metabolism, as a novel noninvasive method for NASH diagnosis.

Methods: Sixty-five patients with biopsy proven nonalcoholic fatty liver disease (NAFLD) and 17 healthy controls were enrolled. Blood samples were obtained from all subjects five times during the OCTT (before and 1, 2, 3, and 4 h after oral loading with 260 mg choline).

Results: Four-hour fCh levels after oral loading choline were markedly increased in NASH patients, compared with non-NASH subjects. For detecting NASH, compared with non-NASH subjects, the area under the curve for 4-h fCh levels was 0.829 on receiver operating characteristic (ROC) analysis. The cut-off level for NASH diagnosis was ≥0.16 mg/dL, and the sensitivity, specificity, positive predictive value, and negative predictive value were 80.1, 82.6, 78.4, and 84.4 %, respectively. Moreover, 4-h fCh levels were significantly associated with the disease activity based on NAFLD activity score in patients with NAFLD.

Conclusions: Four-hour fCh levels obtained by an OCTT reflect a NASH specific disorder of choline metabolism, suggesting that the OCTT is a novel and useful noninvasive method for diagnosing NASH at an early stage with sufficient accuracy for clinical practice.

Citing Articles

In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations.

Lee Y, Seki E Cell Mol Gastroenterol Hepatol. 2023; 16(3):355-367.

PMID: 37270060 PMC: 10444957. DOI: 10.1016/j.jcmgh.2023.05.010.


Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver.

Niikura T, Imajo K, Ozaki A, Kobayashi T, Iwaki M, Honda Y Diagnostics (Basel). 2020; 10(3).

PMID: 32111021 PMC: 7151007. DOI: 10.3390/diagnostics10030129.


Nonalcoholic fatty liver disease in Asia: emerging perspectives.

Seto W, Yuen M J Gastroenterol. 2016; 52(2):164-174.

PMID: 27637587 DOI: 10.1007/s00535-016-1264-3.


Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Ferslew B, Johnston C, Tsakalozou E, Bridges A, Paine M, Jia W Clin Pharmacol Ther. 2015; 97(4):419-27.

PMID: 25669174 PMC: 4499311. DOI: 10.1002/cpt.66.


LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.

Imajo K, Hyogo H, Yoneda M, Honda Y, Kessoku T, Tomeno W PLoS One. 2014; 9(12):e115403.

PMID: 25541989 PMC: 4277307. DOI: 10.1371/journal.pone.0115403.

References
1.
Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

2.
Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K . Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol. 2008; 8:53. PMC: 2621235. DOI: 10.1186/1471-230X-8-53. View

3.
. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20(7):1183-97. DOI: 10.2337/diacare.20.7.1183. View

4.
Hui J, Farrell G, Kench J, George J . High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology. 2004; 39(5):1458-9. DOI: 10.1002/hep.20223. View

5.
Guha I, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S . Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2007; 47(2):455-60. DOI: 10.1002/hep.21984. View